Medical Industry Feature

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Kormal Jhaveri, MD, FACP Guest: Vanessa Soto-Romano, RN There’s been recent progress with antibody-drug conjugates (ADCs) for HER2-negative breast cancers,1-3 and most recently, patients with metastatic HR+ HER2- breast cancer. The phase III TROPION-Breast01 study examined the efficacy and safety of datopotamab deruxtecan-dInk (Dato-DXd) compared to investigator’s choice single-agent chemotherapy, resulting in the approval of this agent in January 2025. Joining Dr. Charles Turck to discuss Dato-DXd for patients with HR-positive, HER2-negative metastatic breast cancer, data from the TROPION-Breast01 trial, and strategies for managing select adverse reactions with this therapy are Dr. Komal Jhaveri and Nurse Vanessa Soto-Romano. Dr. Jhaveri is a breast medical oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center in New York, and Nurse Soto-Romano is a Clinical Trials Nurse, also at Memorial Sloan Kettering Ca